FDA recalls Verapamil Hydrochloride injectable due to cross contamination
FDA is recalling 8,020 vials of Verapamil Hydrochloride Injection (Lot L300269) distributed nationwide due to potential cross contamination with other products.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recalls are typically assigned severity 1-2 per the rubric. No illnesses or injuries are reported in the source. The cross-contamination hazard is theoretical without evidence of patient impact, warranting Moderate classification.
Plain-English summary
Zydus Pharmaceuticals (USA) Inc. is recalling Verapamil Hydrochloride Injection, USP 10 mg/4 mL. The recall affects 8,020 vials of Lot L300269 (expiration date 07/31/2025) distributed nationwide in the United States. The recall was initiated due to potential cross contamination with other products.
Affected vials can be identified by NDC 70710-1644-1 (vial) and NDC 70710-1644-5 (carton). Healthcare providers should verify whether they have received product from this lot.
The recalled product
- Product
- VERAPAMIL HYDROCHLORIDE (VERAPAMIL HYDROCHLORIDE)
- Brand
- VERAPAMIL HYDROCHLORIDE
- Manufacturer
- Zydus Pharmaceuticals (USA) Inc
- Category
- Drug — Intravenous Medication
- Hazard
- cross-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot L300269
- Exp Date 07/31/2025
UPCs (2)
- 0370710164379
- 0370710164355
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · VERAPAMIL HYDROCHLORIDE
- ModerateInjectable Verapamil Hydrochloride Recalled Due to Cross Contamination Risk
FDA (Drugs) · 2024-07-17
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27